TY - JOUR
T1 - Relation between microRNA expression and progression and prognosis of gastric cancer
T2 - a microRNA expression analysis
AU - Ueda, Tetsuya
AU - Volinia, Stefano
AU - Okumura, Hiroshi
AU - Shimizu, Masayoshi
AU - Taccioli, Cristian
AU - Rossi, Simona
AU - Alder, Hansjuerg
AU - Liu, Chang gong
AU - Oue, Naohide
AU - Yasui, Wataru
AU - Yoshida, Kazuhiro
AU - Sasaki, Hiroki
AU - Nomura, Sachiyo
AU - Seto, Yasuyuki
AU - Kaminishi, Michio
AU - Calin, George A.
AU - Croce, Carlo M.
N1 - Funding Information:
We thank Karen F Phillips (Department of Scientific Publications, University of Texas MD Anderson Cancer Center) for editorial assistance. This research was supported by Program Project Grants from the National Cancer Institute (CMC) and in part by an NIH grant 1R01CA135444 . GAC is supported as a fellow at the University of Texas MD Anderson Research Trust, as a fellow of the University of Texas System Regents Research Scholar, and by the Ladjevardian Regents Research Scholar Fund. SV was supported by AIRC and Regione Emilia-Romagna PRRIITT grants.
PY - 2010/2
Y1 - 2010/2
N2 - Background: Analyses of microRNA expression profiles have shown that many microRNAs are expressed aberrantly and correlate with tumorigenesis, progression, and prognosis of various haematological and solid tumours. We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer. Methods: 353 gastric samples from two independent subsets of patients from Japan were analysed by microRNA microarray. MicroRNA expression patterns were compared between non-tumour mucosa and cancer samples, graded by diffuse and intestinal histological types and by progression-related factors (eg, depth of invasion, metastasis, and stage). Disease outcome was calculated by multivariable regression analysis to establish whether microRNAs are independent prognostic factors. Findings: In 160 paired samples of non-tumour mucosa and cancer, 22 microRNAs were upregulated and 13 were downregulated in gastric cancer; 292 (83%) samples were distinguished correctly by this signature. The two histological subtypes of gastric cancer showed different microRNA signatures: eight microRNAs were upregulated in diffuse-type and four in intestinal-type cancer. In the progression-related signature, miR-125b, miR-199a, and miR-100 were the most important microRNAs involved. Low expression of let-7g (hazard ratio 2·6 [95% CI 1·3-4·9]) and miR-433 (2·1 [1·1-3·9]) and high expression of miR-214 (2·4 [1·2-4·5]) were associated with unfavourable outcome in overall survival independent of clinical covariates, including depth of invasion, lymph-node metastasis, and stage. Interpretation: MicroRNAs are expressed differentially in gastric cancers, and histological subtypes are characterised by specific microRNA signatures. Unique microRNAs are associated with progression and prognosis of gastric cancer. Funding: National Cancer Institute.
AB - Background: Analyses of microRNA expression profiles have shown that many microRNAs are expressed aberrantly and correlate with tumorigenesis, progression, and prognosis of various haematological and solid tumours. We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer. Methods: 353 gastric samples from two independent subsets of patients from Japan were analysed by microRNA microarray. MicroRNA expression patterns were compared between non-tumour mucosa and cancer samples, graded by diffuse and intestinal histological types and by progression-related factors (eg, depth of invasion, metastasis, and stage). Disease outcome was calculated by multivariable regression analysis to establish whether microRNAs are independent prognostic factors. Findings: In 160 paired samples of non-tumour mucosa and cancer, 22 microRNAs were upregulated and 13 were downregulated in gastric cancer; 292 (83%) samples were distinguished correctly by this signature. The two histological subtypes of gastric cancer showed different microRNA signatures: eight microRNAs were upregulated in diffuse-type and four in intestinal-type cancer. In the progression-related signature, miR-125b, miR-199a, and miR-100 were the most important microRNAs involved. Low expression of let-7g (hazard ratio 2·6 [95% CI 1·3-4·9]) and miR-433 (2·1 [1·1-3·9]) and high expression of miR-214 (2·4 [1·2-4·5]) were associated with unfavourable outcome in overall survival independent of clinical covariates, including depth of invasion, lymph-node metastasis, and stage. Interpretation: MicroRNAs are expressed differentially in gastric cancers, and histological subtypes are characterised by specific microRNA signatures. Unique microRNAs are associated with progression and prognosis of gastric cancer. Funding: National Cancer Institute.
UR - http://www.scopus.com/inward/record.url?scp=75249107416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75249107416&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(09)70343-2
DO - 10.1016/S1470-2045(09)70343-2
M3 - Article
C2 - 20022810
AN - SCOPUS:75249107416
SN - 1470-2045
VL - 11
SP - 136
EP - 146
JO - The lancet oncology
JF - The lancet oncology
IS - 2
ER -